Targeted drug shows promise for rare blood disorder in early trial
NCT ID NCT05102370
First seen Nov 06, 2025 · Last updated May 22, 2026 · Updated 31 times
Summary
This study tested a drug called enasidenib in 4 adults with clonal cytopenia of undetermined significance (CCUS) who have a specific gene change (IDH2). The goal was to see if the drug is safe and can improve low blood cell counts. Enasidenib works by blocking the faulty IDH2 protein, which may help the body make more healthy blood cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cleveland Clinic (Data Collection Only)
Cleveland, Ohio, 44195, United States
-
Mayo Clinic (Data Collection Only)
Rochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering Bergen (Limited protocol activities)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065, United States
-
Memorial Sloan Kettering Monmouth (All protocol activities)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Limited protocol activities)
Rockville Centre, New York, 11553, United States
-
Memorial Sloan Kettering Suffolk-Commack (Limited protocol activities)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York, 10604, United States
-
Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)
Basking Ridge, New Jersey, 07920, United States
-
Ohio State University (Data Collection Only)
Columbus, Ohio, 43210, United States
-
Oregon Health & Science University (Data Collection Only)
Portland, Oregon, 97239, United States
-
Washington University (Data Collection and Specimen Analysis)
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.